Complications of Urgent-Start Peritoneal Dialysis

Peritoneal dialysis offers benefits to patients with end-stage renal disease (ESRD) in terms of lifestyle flexibility and preservation of residual kidney function. However, worldwide, most patients with uremia are treated with hemodialysis. Reasons for the underutilization of peritoneal dialysis include a low level of experience initiating the modality in patients with ESRD, particularly those with severe symptoms of uremia and ... Read More »

PCI versus Optimal Medical Management in Patients with Advanced Chronic Kidney Disease

Coronary artery disease is a common comorbidity in individuals with advanced chronic kidney disease (CKD). Patients with CKD and coronary artery disease may benefit from cardiovascular procedures, such as percutaneous coronary intervention (PCI), that require use of intravenous contrast. However, use of contrast dye may result in contrast-induced nephrology (CIN). In patients with advanced CKD, CIN may precipitate the need ... Read More »

Incidence of Renal Replacement Therapy in Elderly Patients in Nephrology Care

Recent estimates put the population prevalence of chronic kidney disease (CKD) in the United States at 13%. CKD affects patients of all ages, but there is a strong positive association of CKD with age; the prevalence of CKD among individuals >70 years of age is 50%. Among elderly patients diagnosed with stable CKD stage 3, management by the primary care ... Read More »

September 2017: Abstract Roundup

ACUTE KIDNEY INJURY Diagnoses Associated with Hospital-Acquired AKI Clinical Journal of the American Society of Nephrology. 2017;12(6):874-884 Researchers in France conducted a retrospective analysis of the association between hospital-acquired acute kidney injury (AKI) and each International Classification of Diseases-Tenth Revision (ICD-10) category to identify the diagnoses associated with AKI. The analysis included data on hospital stays for 126,736 unique individuals. ... Read More »

September 2017: News Briefs

Veltassa Approved in European Union Market In late July, Relypsa, Inc., announced that Veltassa® (patiromer) received approval from the European Commission for its Marketing Authorization Application. Patiromer is indicated for the treatment of hyperkalemia (elevated levels of blood potassium). Veltassa is the brand name for patiromer in both the United States and Europe; it is approved for marketing in all ... Read More »

Tolvaptan Reduces Incidence of Kidney Pain in Patients with ADPKD

Patients with autosomal dominant polycystic kidney disease (ADPKD) often experience pain, a symptom reported early in the course of the disease. The pain associated with ADPKD can be severe and a challenge to manage as well as a complication that has an adverse effect on a patient’s quality of life. ADPKD-related acute pain may be caused by cyst hemorrhage, infection, ... Read More »

Dialysate Potassium Level and Adverse Events in Patients on Hemodialysis

In patients requiring hemodialysis, sudden death is a leading cause of death; 27% of all deaths in that patient population are attributable to arrhythmic mechanisms. In patients on maintenance hemodialysis three times a week, these events tend to cluster in the period just prior to the first dialysis session of the week when fluid overload and levels of various uremic ... Read More »

Treating Children and Adolescents with ESRD: A Guide for Nephrologists

It is rare for children to be diagnosed with end-stage renal disease (ESRD); there are approximately 8500 children with ESRD in the United States, according to the most recent US Renal Data System report. Each year, approximately 1500 children in the United States develop ESRD; two-thirds of those patients initiate treatment with hemodialysis and one-third initiate treatment with peritoneal dialysis. ... Read More »

July/August 2017: Abstract Roundup

CHRONIC KIDNEY DISEASE Benefits of Phosphorus Binder Use among Non-Dialysis CKD Patients American Journal of Nephrology. 2017;45(5);431-441. It is unknown whether the benefits of phosphorus binders extend to patients with chronic kidney disease (CKD) but without end-stage renal disease. In a retrospective cohort study conducted by Simran Bhandari, MD, and colleagues, the researchers sought to evaluate phosphorus binder use and ... Read More »

July/August 2017: News Briefs

KDIGO Issues Updated Guidelines for Treatment of CKD-MBD In late June, the Kidney Disease Improving Global Outcomes (KDIGO) updated its Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The update amends the 2009 KDIGO Clinical Practice Guideline and includes revised positions on standards of care for the treatment of secondary hyperparathyroidism ... Read More »